RxDoctor Payments Data

Bonnie Warner, APRN

Family · Louisville, KYNPI 1013200534

Payments from drug & device makers

$9,029in general payments, 2019–2025

Across 534 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Amgen$970
  • Boehringer Ingelheim$817
  • Pfizer$766
  • Biohaven Pharmaceutical Holding Company Ltd.$487
  • plus $4K from 24 others

What the payments were for

  • Food & beverage$9,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,029 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$61,513
Medicare patients
195
Services billed
2,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$75,861
MounjaroTirzepatide38$69,874
JanuviaSitagliptin Phosphate25$28,009
FarxigaDapagliflozin Propanediol27$27,490
RybelsusSemaglutide23$25,446
TradjentaLinagliptin21$18,916
Soliqua 100-33Insulin Glargine/Lixisenatide15$17,855
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,335
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$6,431
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen191$4,087
Atorvastatin Calcium534$3,381
Metoprolol Succinate188$2,685
Levothyroxine Sodium186$2,461
Potassium Chloride98$2,071
Omeprazole178$1,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$766$75,86176 claims
Lilly USA, LLCMounjaro$296$69,87438 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,220$41,82542 claims
MerckJanuvia$83$28,00925 claims
Novo NordiskRybelsus$1,004$25,44623 claims
Boehringer IngelheimTradjenta$817$18,91621 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$375$17,85515 claims
AbbVieSynthroid$425$66417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →